Beckman Coulter will be using a grant from BARDA (the Biomedical Advanced Research and Development Authority, a division of the Dept. of Health and Human Services) to validate the ability of the company’s Monocyte Distribution Width (MDW) hematology biomarker to aid in the rapid detection of a rare but serious complication of Covid-19 affecting children. 

Results from an early safety study of Moderna Inc.’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said.